Aspirin for the primary prevention of cardiovascular events: A summary of the evidence for the U.S. Preventive Services Task Force

Annals of Internal Medicine

Volumn 136, Issue 2, 2002, Pages 161-172

  Hayden, Michael ^a   Pignone, Michael ^a   Phillips, Christopher ^a   Mulrow, Cynthia ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

CARDIOVASCULAR DISEASE; DIABETES MELLITUS; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MEDICAL DECISION MAKING; META ANALYSIS; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL MODEL; STROKE; UNITED STATES;

EID: 0037080065     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-136-2-200201150-00016     Document Type: Review

References (34)

1. Aspirin and risk of hemorrhagic stroke: A meta-analysis of randomized controlled trials
2. Final report on the aspirin component of the ongoing Physicians' Health Study
3. Randomised trial of prophylactic daily aspirin in British male doctors
4. Guide to Clinical Preventive Services
5. Thrombosis prevention trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk
6. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
7. Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomised trial in general practice
8. Baseline characteristics of participants in the Women's Health Study
9. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14
10. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris
11. Aspirin: Benefit and risk in thromboprophylaxis
12. The gastrointestinal toxicity of aspirin: An overview of randomised controlled trials
13. Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events. A critical analysis
14. Efficacy and safety of different aspirin dosages on vascular diseases in high-risk patients. A metaregression analysis
15. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product
16. Aspirin for the primary prevention of stroke and other major vascular events: Meta-analysis and hypotheses
17. Prophylactic aspirin and risk of peptic ulcer bleeding
18. Adverse effects of low-dose aspirin in a healthy elderly population
19. Determination of who may derive most benefit from aspirin in primary prevention: Subgroup results from a randomised controlled trial
20. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration
21. Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment
22. Anthithrombotic treatment
23. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study
24. Risk of primary intracerebral haemorrhage associated with aspirin and non-steroidal anti-inflammatory drugs: Case-control study
25. Risk of gastrointestinal haemorrhage with long term use of aspirin: Meta-analysis
26. Aspirin as a therapeutic agent in cardiovascular disease: A statement for healthcare professionals from the American Heart Association
27. Prediction of coronary heart disease using risk factor categories
28. Validation of the Framingham coronary heart disease prediction scores: Results of a multiple ethnic groups investigation
29. Aspirin for primary prevention of cardiovascular events
30. An overview of the 4 randomized trials of aspirin therapy in the primary prevention of vascular disease
31. Aspirin for primary prevention of coronary heart disease: Safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials